Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.
12/21/2001
Biogen Says 2001 Revenues Will Exceed $1 Billion
12/18/2001
11/02/2001
BIOGEN ANNOUNCES NEW APPOINTMENTS IN ITS INTERNATIONAL OPERATION
11/01/2001
BIOGEN CITES GOAL OF SURPASSING $2 BILLION IN REVENUES IN 2005
10/29/2001
$1 MILLION “BIOGEN LEGACY FUND” ESTABLISHED, DONATED TO “FAMILIES OF FREEDOM SCHOLARSHIP FUND™”
10/25/2001
BIOGEN APPOINTS THOMAS BUCKNUM, ESQ. EXECUTIVE VICE PRESIDENT & GENERAL COUNSEL
10/25/2001
BIOGEN APPOINTS FRANK A. BURKE, JR. EXECUTIVE VICE PRESIDENT, HUMAN RESOURCES
10/25/2001
BIOGEN APPOINTS PETER N. KELLOGG EXECUTIVE VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER
10/16/2001
THIRD QUARTER 2001 EARNINGS PER SHARE INCREASED TO $0.46 FROM $0.44 IN 2000
10/05/2001
10/01/2001
BIOGEN APPOINTS BURT ADELMAN, M.D., EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT
09/06/2001
08/27/2001
BIOGEN APPOINTS SYLVIE GRéGOIRE, Pharm. D.,EXECUTIVE VICE PRESIDENT, TECHNICAL OPERATIONS
08/18/2001
SWISS COURT RULES IN FAVOR OF BIOGEN, UPHOLDS INJUNCTION AGAINST SERONO
08/16/2001
08/06/2001
BIOGEN COMPLETES INTERNATIONAL REGISTRATIONAL FILING
08/01/2001
BIOGEN FILES FOR ARBITRATION AGAINST SCHERING-PLOUGH
08/01/2001
BIOGEN APPOINTS HANS-PETER HASLER EXECUTIVE VICE PRESIDENT, COMMERCIAL OPERATIONS
07/17/2001
BIOGEN REPORTS SECOND QUARTER 2001 RESULTS
07/16/2001
ICOS AND BIOGEN COLLABORATE TO DEVELOP ORAL THERAPEUTICS FOR AUTOIMMUNE AND INFLAMMATORY DISEASES
06/22/2001
05/23/2001
ANTEGREN® (natalizumab) PHASE II DATA SHOW PROMISING RESULTS IN CROHN’S DISEASE
05/15/2001
BIOGEN SELECTS DENMARK’S “MEDICON VALLEY” AS SITE FOR ITS FIRST INTERNATIONAL MAJOR MANUFACTURING FACILITY
05/08/2001
04/12/2001
BIOGEN REPORTS RECORD RESULTS FOR FIRST QUARTER 2001
04/04/2001
Biogen Schedules First Quarter 2001 Financial Results for April 12, 2001
03/27/2001
BIOGEN REAFFIRMS FIRST QUARTER AND FULL YEAR 2001 GUIDANCE WITH UPDATE ON ROYALTY REVENUE STATUS
03/26/2001
BIOGEN LAUNCHES MSACTIVESOURCE.COM
03/19/2001
03/05/2001
02/22/2001
BIOGEN APPOINTS DR. TOSHIO NAKATA PRESIDENT, BIOGEN JAPAN LTD. AND VICE PRESIDENT, BIOGEN INC.
02/02/2001
BIOGEN NAMES PATRICK J. PURCELL VICE PRESIDENT, CHIEF INFORMATION OFFICER
01/22/2001
01/17/2001
BIOGEN REPORTS FOURTH QUARTER AND 2000 RESULTS
01/09/2001
BIOGEN SAYS IT EXPECTS NUMBER OF DRUGS IN CLINICAL PIPELINE TO DOUBLE IN 2001
01/08/2001
Biogen, Inc. to Provide Company Update at Chase H&Q Healthcare Conference in San Francisco